


PRODUCT INFORMATION



BMS 986278

Item No. 43597

CAS Registry No.: 2170126-74-4
Formal Name: (1S,3S)-3-[[[2-methyl-6-[1-methyl-5-[[[(methylpropylamino)carbonyl]oxy]methyl]-1H-1,2,3-triazol-4-yl]-3-pyridinyl]oxy]-cyclohexanecarboxylic acid
Synonym: Admilparant
MF: C₂₂H₃₁N₅O₅
FW: 445.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BMS 986278 is supplied as a solid. A stock solution may be made by dissolving the BMS 986278 in the solvent of choice, which should be purged with an inert gas. BMS 986278 is soluble (≥10 mg/ml) in DMSO. BMS 986278 is sparingly soluble (1-10 mg/ml) in ethanol.

Description

BMS 986278 is an antagonist of lysophosphatidic acid receptor 1 (LPA₁; K_b = 0.0069 μM).¹ It is selective for LPA₁ over a panel of 44 receptors, ion channels, and enzymes when used at concentrations ranging from 30 to 150 μM, including the bile salt export pump (BSEP), multidrug resistance protein 3 (MDR3), multidrug resistance-associated protein 3 (MRP3), MRP4, organic anion transporting polypeptide 1B1 (OATP1B1), and OATP1B3 (IC₅₀s = >100, >100, 66, 47, 36, and 10 μM, respectively). BMS 986278 inhibits LPA-induced histamine release in mice in a dose-dependent manner. Oral administration of BMS 986278 (3 and 10 mg/kg) reduces bleomycin-induced lung fibrosis in rats. Unlike BMS 986020 (Item No. 22049), BMS 986278 does not induce bile duct hyperplasia, cholangitis, or cholestasis in cynomolgus monkeys.²

References

1. Cheng, P.T.W., Kaltenbach, R.F., III, Zhang, H., *et al.* Discovery of an oxycyclohexyl acid lysophosphatidic acid receptor 1 (LPA1) antagonist BMS-986278 for the treatment of pulmonary fibrotic diseases. *J. Med. Chem.* **64**(21), 15549-15581 (2021).
2. Sivaraman, L., Gill, M., Nelson, D.M., *et al.* Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA₁) antagonists. *Toxicol. Appl. Pharmacol.* **438**, 115846 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/27/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM